Iqvia (IQV) and Veeva (VEEV) announced global clinical and commercial partnerships and the complete resolution of all pending legal disputes. Under the terms of the long-term agreement, customers can use software, data, technology, and service offerings from Veeva and Iqvia together. The global partnerships allows customers to work with Iqvia and Veeva in key areas including: the companies have established master data and software third-party access agreements that allow Iqvia or Veeva data to be used with each other’s software or services in customer instances; Iqvia has joined Veeva’s CRO Clinical Data Partner program and can leverage the Veeva Clinical Suite to execute clinical trials using Veeva software products, including study builds with Veeva EDC.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Veeva Systems: Strong Client Retention and Product Innovation Drive Buy Rating
- Six of top 20 pharma companies committed to Veeva Vault CRM, says Barclays
- Oppenheimer sees Merck agreement as strong endorsement for Veeva’s Vault CRM
- Veeva Systems’ Strong Market Position and Growth Potential: A Buy Rating by Dylan Becker
- Veeva announces Merck committed to Veeva Vault CRM